Ontario HIV Treatment Network (OHTN) Cohort Study Fact Sheet
What were the main results of the study? Overall, 58% of the 778 study participants had lipodystrophy (41% had lipoatrophy, while 31% had lipohypertrophy). There was no difference between black, white and other participants regarding the presence of lipodystrophy or central lipohypertrophy or the severity of central lipohypertrophy. White participants were more likely to experience peripheral lipoatrophy (45%) than black participants (30%) or others (36%). Of those who did experience peripheral lipoatrophy, white and other participants reported a greater severity than black participants.
Males and females did not differ in the prevalence of overall lipodystrophy, but males were more likely to experience peripheral lipoatrophy (43% vs 30%), while females were more likely to experience central lipohypertrophy (47% vs 28%). After adjusting for length of time on ART, black women emerged as the group most vulnerable to lipodystrophy, which is consistent with previous study findings. The finding that ART-associated peripheral lipoatrophy is more common in white patients is also consistent with available literature.
What do the study results mean for the treatment and care of people living with HIV?
The results of the study confirm that ethnicity and gender are important factors that contribute to the development and manifestations of ART-associated lipoatrophy among PHAs. Patients who suffer from lipodystrophy are also prone to other metabolic toxicities including impaired glucose tolerance, insulin resistance and dyslipidaemia, leading to increased risk of diabetes and cardiovascular disease. It is increasingly important to consider the implications of ethnic and gender variations in all ART-associated side effects to help guide clinical decision-making regarding specific ARVs. Study results regarding the vulnerability of black women to lipodystrophy (especially central lipohypertrophy) have particular implications for the rollout of ART in sub-Saharan Africa, where women are disproportionately affected by the HIV epidemic.
Where can I find the full-length publication of this study? This study was published in HIV Clinical Trials. The full text version is available at: http://www.ncbi.nlm.nih.gov/pubmed/21498152.
The Ontario HIV Treatment Network Cohort Study (OCS) is an ongoing research study that collects clinical, social and behavioural information about people living with HIV (PHA) in Ontario. Participation in the study is voluntary, and all personally identifying information of study participants is removed to ensure confidentiality. The OCS was established to improve our understanding of HIV and to inform HIV prevention, care and treatment strategies for people living with HIV and groups at increased risk of HIV infection. For more information about the OCS, please contact the OCS Research Coordinator, Brooke Ellis at: bellis@ohtn.on.ca.
